

This is a repository copy of *Patient-reported outcomes in randomised controlled trials of gynaecological cancers: Investigating methodological quality and impact on clinical decision-making.*

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/88845/

Version: Accepted Version

Article:

Efficace, F, Jacobs, M, Pusic, A et al. (6 more authors) (2014) Patient-reported outcomes in randomised controlled trials of gynaecological cancers: Investigating methodological quality and impact on clinical decision-making. European journal of cancer, 50 (11). 1925 - 1941. ISSN 0959-8049

https://doi.org/10.1016/j.ejca.2014.04.005

© 2014. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/

Reuse


Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/ Fig.1 - Schematic breakdown of literature search results of Gynecological Randomised Controlled Trials (Preferred Reporting Items for Systematic Reviews and Meta-analysis).



PRO= patient-reported outcomes.

Table 1. RCT demographic characteristics.

		PRO en	dpoint n (%)	
Variable Basic RCT demographics		Primary 8 (16%)	Secondary 42 (84%)	Total n (%)
Anatomic site of cancer	Cervical	2 (25)	7 (16.675)	9 (18)
	Endometrial	2 (25)	6 (14.29)	8 (16)
	Ovarian	1 (12.50)	15 (35.72)	16 (32)
	Multiple disease sites	3 (37.50)	14 (33.33)	17 (34)
nternational	No	6 (75)	23 (54.76)	29 (58)
	Yes	2 (25)	19 (45.24)	21 (42)
ndustry supported (fully or in part)*	No	7 (87.5)	17 (40.48)	24 (48)
	Yes	1 (12.5)	25 (59.52)	26 (52)
Overall study sample size	≤ 200 patients	6 (75)	13 (30.95)	19 (38)
regardless of patients included in the PRO analysis)	> 200 patients	2 (25)	29 (69.05)	31 (62)
	Advanced/metastatic	2 (25)	14 (33.33)	16 (32)
	Locoregional/no distant	5 (62.5)	5 (11.9)	10 (20)
Disease stage	metastasis			
	Mixed disease stages	1 (12.5)	22 (52.38)	23 (46)
	Unclear	0 (0)	1 (2.38)	1 (2)
	Radiotherapy	2 (25)	7 (16.67)	9 (18)
	Surgery	4 (50)	6 (14.29)	10 (20)
Broad treatment type	Chemotherapy	3 (37.50)	36 (85.71)	39 (78)
	Target therapy	2 (25)	1 (2.38)	3 (6)
Difference between treatment arms in the	No	0 (0)	20 (47.62)	20 (40)
primary endpoint	Yes	8 (100)	22 (52.38)	30 (60)
	No	1 (12.5)	28 (66.67)	29 (58)
Overall Survival (OS) difference favoring	Yes	0 (0)	7 (16.67)	7 (14)
experimental treatment	N/A (in case OS was not	7 (87.5)	7 (16.67)	14 (28)
PRO-related basic characteristics	assessed)			
	EORTC Instruments	3 (37.50)	21 (50)	24 (48)
	FACT Instruments	2 (25)	14 (33.33)	16 (32)
PRO instrument used	VAS	2 (25)	1 (2.38)	3 (6)
	Others	1 (12.5)	6 (14.29)	7 (14)
				19 (38)
	No differences at all	1 (12.5)	18 (42.86)	
	Yes broadly favoring experimental treatment †	7 (87.5)	12 (28.57)	19 (38)
PRO difference between treatment arms	Yes broadly favoring	0 (0)	11 (26.19)	11 (22)
	standard treatment +			. ,
	N/A	0 (0)	1 (2.38)	1 (2)
	Symptoms only	3 (42.86)	6 (26.09)	9 (30)
If statistically significant PRO difference exists, in which domain?	PRO domains other than symptoms only (e.g. functional scales or global QoL)	0 (0)	4 (17.39)	4 (13.33)
	Both domains (symptoms + domains other than symptoms)	4 (57.14)	13 (56.52)	17 (56.67)
	Up to 6 months	8 (100)	15 (35.71)	23 (46)
Length of PRO assessment during RCT	Up to 1 year	0 (0)	13 (30.95)	13 (26)
-	More than 1 year	0 (0)	14 (33.33)	14 (28)
	No	7 (87.5)	30 (71.43)	37 (74)
Secondary paper on PRO‡	Yes	1 (12.5)	12 (28.57)	13 (26)

Legend: * Assessed if explicitly stated or if one or more authors were affiliated to a pharmaceutical company. This evaluation is based solely on information extracted from the paper. ⁺ Often, multiple PRO domains (e.g. from multidimensional HRQOL questionnaires) are analyzed at the same time in longitudinal PRO-RCTs; to illustrate, difference in such domains might favor the experimental treatment arm at a given time-point and then favoring the control treatment arm at a different time point over the course of the study. So, the term "broadly" was inserted to account for this possible discrepancy; [‡] Assessed as "yes" if at least one paper was published in addition to the original RCT report.

Table 2 Level of Patient-Reported Outcomes (PRO) reporting by type of endpoint (PRO primary versus secondary endpoint of the trial).

		PRO en	dpoint n (%)	
		Primary 8 (16%)	Secondary 42 (84%)	Total n (%)
TITLE AND ABSTRACT				
The PRO should be identified as an outcome	No	2 (25)	10 (23.81)	12 (24)
in the abstract	Yes	6 (75)	32 (76.19)	38 (76)
The title of the paper should be explicit as to	No	4 (50)	-	4 (50)
the RCT including a PRO	Yes	4 (50)	-	4 (50)
INTRODUCTION, BACKGROUND AND OF		1 (30)		1 (30)
The PRO hypothesis should be stated and	No	7 (87.5)	36 (85.71)	43 (86)
should specify the relevant PRO domain if	Yes	1 (12.5)	4 (9.52)	5 (10)
applicable	N/A (if explorative)	0 (0)	2 (4.76)	2 (4)
	,		2 (4.70)	
The introduction should contain a summary	No	3 (37.5)	-	3 (37.5)
of PRO research that is relevant to the RCT	Yes	5 (62.5)	-	5 (62.5)
Additional details regarding the hypothesis should be provided, including the rationale for the selected domain(s), the expected direction(s) of change, and the time points for assessment	No	8 (100)	-	8 (100)
METHODS				
Outcomes				
The mode of administration of the PRO tool	No	7 (87.5)	35 (83.33)	42 (84)
and the methods of collecting data should be described	-	1 (12.5)	7 (16.67)	8 (16)
Electronic mode of PRO administration*	No	1 (12.5)	7 (16.67)	8 (16)
	N/A	7 (87.5)	35 (83.33)	42 (84)
The rationale for choice of the PRO	No	8 (100)	24 (90.05)	42 (94)
instrument used should be provided	Yes	8 (100)	34 (80.95) 8 (19.05)	42 (84) 8 (16)
instrument used should be provided	Tes	0 (0)	8 (19.05)	8 (10)
Evidence of PRO instrument validity and	No†	4 (50)	8 (19.05)	12 (24)
reliability should be provided or cited	Yes	4 (50)	34 (80.95)	38 (76)
The intended PRO data collection schedule	No	2 (25)	6 (14.29)	8 (16)
should be provided	Yes	6 (75)	36 (85.71)	42 (84)
PROs should be identified in the trial protocol post-hoc analyses should be identified	No Yes	6 (75) 2 (25)	28 (66.67) 14 (33.33)	34 (68) 16 (32)
The status of PRO as either a primary or	No	1 (12.5)	0 (0)	10(32)
secondary outcome should be stated	Yes	5 (62.5)	39 (92.86)	44 (88)
secondary outcome should be stated	Unclear	2 (25)	39 (92.86)	5 (10)
	Unclear	2 (25)	3 (7.14)	5 (10)
A citation for the original development of the	No [†]	5 (62.5)	-	5 (62.5)
PRO instrument should be provided	Yes	3 (37.5)	-	3 (37.5)
Windows for valid PRO responses should be	No	7 (87.5)	_	7 (87.5)
specified and justified as being appropriate	Yes	1 (12.5)	-	1 (12.5)
for the clinical context		- ()		- (-2.3)
Sample size	I			
There should be a power sample size	No	5 (62.5)	-	5 (62.5)
calculation relevant to the PRO based on a	Yes	3 (37.5)	-	3 (37.5)
clinical rationale		5 (57.5)		0 (07.07
Statistical methods	I			
There should be evidence of appropriate	Yes	1 (12.5)	4 (9.52)	5 (10)
statistical analysis and tests of statistical	N/A (If PRO	7 (87.5)	38 (90.48)	45 (90)
significance for each PRO hypothesis tested	hypotheses were not stated)	7 (07.5)	50 (50.48)	43 (30)
The extent of missing data should be stated ‡	No	3 (37.5)	17 (40.48)	20 (40)
	Yes	5 (62.5)	25 (59.52)	30 (60)
Statistical approaches for dealing with	No	7 (87.5)	34 (80.95)	41 (82)
and a second	Yes	1 (12.5)	8 (19.05)	9 (18)
missing data should be explicitly stated ‡				
	No	5 (62.5)	-	5 (62.5)
missing data should be explicitly stated ‡ The manner in which multiple comparisons have been addressed should be provided	No Yes	5 (62.5) 3 (37.5)	-	5 (62.5) 3 (37.5)

Table 2 (continued). Level of Patient-Reported Outcomes (PRO) reporting by type of endpoint (PRO primary versus secondary endpoint of the trial).

		PRO endpoint n (%)			
		Primary 8 (16%)	Secondary 42 (84%)	Tota n (%	
RESULTS (continued Table 2)		• •			
Participant flow					
A flow diagram or a description of the	No	6 (75)	28 (66.67)	34 (68)	
allocation of participants and those lost to ollow-up should be provided for PROs specifically	Yes	2 (25)	14 (33.33)	16 (32)	
The reasons for missing data should be	No	3 (37.5)	32 (76.19)	35 (70)	
explained	Yes	5 (62.5)	10 (23.81)	15 (30)	
Baseline data					
The study patients characteristics should be	No	3 (37.5)	16 (38.1)	19 (38)	
described including baseline PRO scores	Yes	5 (62.5)	26 (61.9)	31 (62)	
Outcomes and Estimation					
Are PRO outcomes also reported in a	No	4 (50)	22 (52.38)	26 (52)	
graphical format?*	Yes	4 (50)	20 (47.62)	24 (48)	
The analysis of PRO data should account for	No	1 (12.5)	-	1 (12.5)	
survival differences between treatment groups if relevant	N/A (if not relevant)	7 (87.5)	-	7 (87.5)	
Results should be reported for all PRO	No	2 (25)	-	2 (25)	
domains(if multi-dimensional)and items dentified by the reference instrument	Yes	6 (75)	-	6 (75)	
The proportion of patients achieving pre-	No	4 (50)	-	4 (50)	
defined responder definitions should be	Yes	1 (12.5)	-	1 (12.5)	
provided where relevant	N/A (if not relevant)	3 (37.5)	-	3 (37.5)	
DISCUSSION					
Limitations					
The limitations of the PRO components of the	No	6 (75)	21 (50)	27 (54)	
rial should be explicitly discussed	Yes	2 (25)	21 (50)	23 (46)	
Generalizability	103	2 (23)	21 (30)	23 (10)	
Generalizability issues uniquely related to the	No	2 (25)	34 (80.95)	36 (72)	
PRO results should be discussed	Yes	6 (75)	8 (19.05)	14 (28)	
	103	5 (75)	0 (13.03)	14 (20)	
Interpretation Are PRO interpreted? (Not only re-stated)*	No	2 (27 5)	10 (45.24)	22 (44)	
Are PRO Interpreted? (NOt Only re-stated)*	No	3 (37.5)	19 (45.24)	22 (44)	
	Yes	5 (62.5)	23 (54.76)	28 (56)	
The clinical significance of the PRO findings	No	7 (87.5)	28 (66.67)	35 (70)	
should be discussed	Yes	1 (12.5)	14 (33.33)	15 (30)	
Mothodology used to access slipited	Anchorbassel				
Methodology used to assess clinical	Anchor based	0 (0)	3 (21.43)	3 (20)	
significance (in case this was addressed)*	Distribution based	1 (100)	9 (64.29)	10 (66.67)	
	Other	0 (0)	2 (14.29)	2 (13.33)	
he PRO results should be discussed in the	No	2 (25)	20 (47.62)	22 (44)	
context of the other clinical trial outcomes	Yes	6 (75)	22 (52.38)	28 (56)	
OTHER INFORMATION			· · · ·	. ,	
Protocol					
A copy of the instrument should be included if t has not been published previously (It could be found in the article appendix or in the	No	8 (100)	-	8 (100)	

<u>Legend:</u>

For descriptive purposes, subheadings of this table reflect that of reported in the ISOQOL recommended standards, however, rating of items was independent of location of the information within the manuscript; N/A: Not Applicable.

- Indicates items that are not applicable as these are recommended to be reported only when PRO is a primary endpoint; * the following items have not been included in the ISOQOL recommended standards¹⁶ but have been added in this table to have a wider outlook on the level of reporting. † We evaluated as "no" if all PRO measures used in the study were not validated; ‡ These items were originally combined in the ISOQOL recommended standards¹⁶ but have been split in this report to better investigate possible discrepancies between documentation of PRO missing data (i.e., reporting how many patients did not complete a given questionnaire at any given time point) *versus* actual reporting of statistical methods to address this issue. Also, we wanted to be consistent with items reported in the CONSORT PRO Extension (i.e., *statistical approaches for dealing with missing data* is reported as a standalone issue).

Table 3. Randomized Controlled Trials with robust PRO design: basic study characteristics.

Study*	Internat ional	Age of patients (years) †	Overall study sample size	Baseline PRO sample size	PRO instruments used	Primary endpoint	Treatment outline	Summary of main clinical results	Summary of PRO results/PRO treatment recommendations	Anatomic site of cancer
					Metastatic/Advan	ced disease stag	ge			
Kurtz JE et al. Ann Oncol 2011;22(11):24 17-23; Alexandre J et al. Br J Cancer 2012;106(4):63 3-7; Brundage M et al. Ann Oncol 2012; 23(8):2020-7; Gladieff L et al. Ann Oncol 2012; 23(5):1185-9; Joly et al; Gynecol Oncol 2011;122(2):22 6-32; Pujade- Lauraine et al. J Clin Oncol 2010; 28(20):3323-9.	Yes	Median (range) carboplatin– pegylated liposomal doxorubicin (CD): 60.5 (24-82) carboplatin– paclitaxel (CP): 61 (27-82)	976	879	EORTC QLQ- C30; EORTC QLQ- OV28.	progression free- survival.	CD arm: combination of pegylated liposomal doxorubicin (PLD) (30mg/m2 intravenously on day 1) and carboplatin (AUC 5 based on the Calvert formula using glomerular filtration rate calculated from serum creatinine values according to the method of Cockroft and Gault, administered intravenously on day 1 at 4-week intervals. CP arm: combination of paclitaxel (175 mg/m2 intravenously on day 1) and carboplatin (AUC 5 intravenously on day 1) at 3-week intervals. Random assignment was performed in permuted blocks of 6 cycles.	With median follow-up of 22 months, Progression Free- Survival for the pegylated liposomal doxorubicin with carboplatin and paclitaxel arm (hazard ratio, 0.821; 95% CI, 0.72 to 0.94; $P = 0.005$); median Progression Free Survival (PFS) was 11.3 versus 9.4 months, respectively. Overall severe non-hematologic toxicity (36.8% v 28.4%; $P < 0.01$) leading to early discontinuation (15% v 6%; P < 0.001) occurred more frequently in the CP arm.	Global Quality of Life (QoL) and abdominal symptom scores improved over time in both arms; at 6 months, 36% of patients met criteria for improved symptoms. Treatment with CD resulted in less peripheral neuropathy (9.8 versus 24.2), fewer other chemotherapy side-effects (9.5 versus 16.2), and less impact on body image (3.8 versus 10.4) versus CP (all P < 0.02) at 6 months.	Multiple disease sites.

Cella D et al. Gynecol Oncol. 2010;119(3):53 1-7; Monk BJ et al. J Clin Oncol 2009;27(28): 4649-55.	No	Median (range) Vinorelbine (VC) = 49; (24-76) gemcitabine (GC) =45; (20-89) topotecan (TC) = 48; (25-75) paclitaxel (PC) = 50; (29-81)	513	410	FACT-Cx TOI; FACT/GOG- NTX; BPI	Overall survival.	Patients were randomly assigned to paclitaxel 135 mg/m2 over 24 hours plus Cis 50 mg/m2 day 2 every 3 weeks (PC, reference arm); vinorelbine 30 mg/m2 days 1 and 8 plus Cis 50 mg/m2 day 1 every 3 weeks (VC); gemcitabine 1,000 mg/m2 day 1 and 8 plus Cis 50 mg/m2 day 1 every 3 weeks (GC); or topotecan 0.75 mg/m2 days 1, 2, and 3 plus Cis 50 mg/m2 day 1 every 3 weeks (TC). Duration: up to 6 months	No statistically significant difference.	No statistically signficant differences in Health- related Quality of Life (HRQL), neuropathy, or pain.	Cervical
Long HJ et al. J Clin Oncol 2005;23(21): 4626-33; Monk BJ et al. J Clin Oncol 2005;23(21): 4617-25; Long HJ et al. Gynecol Oncol 2006;100(3): 537-43.Long HJ.	No	Cisplatin- topotecan (CT): 46(22-84) Cisplatin (CPT): 48 (27-76)	364	284	FACT-G, FACT-Cx, FACT/GOG- NTX, BPI, UNI.	overall survival.	cisplatin 50 mg/m2 every 3 weeks (CPT); cisplatin 50 mg/m2 IV day 1 plus topotecan 0.75 mg/m2 days 1 to 3 every 21 days (CT) (methotrexate 30 mg/m2 days 1, 15, and 22, vinblastine 3 mg/m2 days 2, 15, and 22, doxorubicin 30 mg/m2 day 2, and cisplatin 70 mg/m2 day 2 every 28 days. methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). Max 6 cycles	Patients receiving cisplatin and topotecan CT had statistically superior outcomes to those receiving cisplatin CPT, with median overall survival of 9.4 and 6.5 months (P = 0.017), median PFS of 4.6 and 2.9 months (P = 0.014), and response rates of 27% and 13%, respectively.	There was no statistical evidence suggesting that reported QoL and adverse effects scores changed over time differently across regimens. Baseline FACT-G (P = 0.0001) and BPI (P = 0.0001) scores were significantly associated with patient age; older patients had better QOL and less pain. Baseline UNI was positively correlated with FACT-G (r = 0.66; P <0.001) and Cx subscale (r= 0.29; P < 0.001), and negatively related to BPI (r=-0.41; P <0.0001). Baseline FACT- Cx (FACT-G + Cx subscale) was associated with survival.	Cervical

Moore DH et al. J Clin Oncol 2004; 22(15):3113-9; McQuellon RP et al. Gynecol Oncol 2006; 101(2):296- 304;	No	Median (range) Cisplatin (C): 46.0 (22-84) Cisplatin plus paclitaxel (CP): 48.5 (21-77)	280	252	FACT-G; FACT-Cx; A Trial Outcome Index representing Physical Well Being (PWB) + Functional Well- Being (FWB) + the Cervix subscale; BPI-SF; neurotoxicity subscale	overall survival; progression free- survival; Objective Response Rate.	Cisplatin (C): IV dose of 50 mg/m2 at the rate of 1 mg/min. Cisplatin plus paclitaxel (CP): paclitaxel IV dose of 135 mg/m2 as a 24-hour infusion followed immediately by cisplatin at a dose of 50 mg/m2 Duration every 3 weeks for 6 cycles	Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving cisplatin plus paclitaxel (P=0.002). The median (PFS) was 2.8 and 4.8 months, respectively, for cisplatin versus cisplatin plus paclitaxel (P < 0.001).	There was no significant difference in QOL scores. The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments. The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) ($P < 0.05$). At the fourth time point, 60% of living patients in both arms completed a QOL assessment.	Cervical
Fleming GF et al. J Clin Oncol 2004; 22(11):2159- 66.	No	<= 50, N=22 51-60 , N=72 61-70, N=110 71-80, N=54 >=81, N=5	273	216	FACT/GOG-NTX	Overall survival.	Doxorubicin cisplatin (AP) doxorubicin 60 mg/m2 and cisplatin 50 mg/m2. Doxorubicin cisplatin paclitaxel (TAP) doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 (day 1), followed by paclitaxel 160 mg/m2 (day 2) with filgrastim support every 3 weeks to a maximum of seven cycles.	Objective response (57% v 34%; P< 0.01), PFS (median, 8.3 v 5.3 months; P=<0.01), and OS (median, 15.3 v 12.3 months; P = 0.037) were improved with TAP.	Following two cycles of chemotherapy, patients on the TAP arm reported a significantly higher neurotoxicity score than did patients on the AP arm. Significant differences in the mean score were observed, and sustained following the second cycle of chemotherapy. Furthermore, patients reported neurotoxicity increased significantly during the treatment period in the TAP arm, but not in the AP arm.	Endometrial
			I	I	Non-metastatic	disease stage	seven eyeles.	1	I	
Armstrong DK et al. N Engl J Med 2006; 354(1):34-43; Wenzel LB et al. J Clin Oncol 2007; 25(4):437-43; von Gruenigen VE et al. Gynecol Oncol 2012;124(3):	No	Intravenous- Therapy (IV) (N = 210) and Intraperitonea I- Therapy (IP) (N = 205) 21-30 0; 4(2) 31-40 15 (7); 8 (4) 41-50 43	429	399	FACT-O; FACT-TOI; FACT-G subscales (PWB, Physical Well Being; FWB, Functional Well- Being, SWB, Social well-being and EWB, Emotional Well- being); FACT / GOG NTX	progression free- survival and overall survival.	Intravenous- therapy (IV): 135 mg of intravenous paclitaxel per square meter of body-surface area over a 24-hour period on day 1 followed by 75 mg of intravenous cisplatin per square meter on day 2. intraperitoneal-	The median duration of progression-free survival in the intravenous-therapy and intraperitoneal-therapy groups was 18.3 and 23.8 months, respectively ($P = 0.05$). The median duration of overall survival in the intravenous-therapy and intraperitonealtherapy groups was 49.7 and 65.6 months, respectively ($P = 0.03$).	Quality of Life was significantly worse in the intraperitoneal-therapy group before cycle 4 and three to six weeks after treatment but not one year after treatment Physical and functional well-being and ovarian cancer symptoms were significantly worse in the IP arm before cycle 4 (P = 0.001) and 3 to 6 weeks after treatment (P =0.001	Multiple disease sites.

379-82;		$(20) \cdot 52 (25)$					therapy (IP): 135		for FACT-TOI).	
Krivak TC et al. Gynecol Oncol 2009; 115(1):81-5.	v	(20); 52 (25) 51–60 74 (35); 62 (30) 61–70 56 (27); 53 (26) 71–80 19 (9); 24 (12) >80 3 (1); 2 (1)	201	222			mg of intravenous paclitaxel per square meter over a 24-hour period on day 1 followed by 100 mg of intraperitoneal cisplatin per square meter on day 2 and 60 mg of intraperitoneal paclitaxel per square meter on day 8 duration: every 3 weeks for 6 cycles.		Patients in the IP arm also reported significantly worse abdominal discomfort (AD) before cycle 4 (P = 0.001) and significantly worse Ntx 3 to 6 weeks (P = 0.001) and 12 months (P = 0.003) after completing IP treatment. In general, however, the quality of life of both groups improved over time.	
Janda M et al. Contemp Clin Trials 2006; 27(4):353-63; Janda M et al. Lancet Oncol 2010; 11(8):772-80.	Yes	Total laparoscopic hysterectomy (TLH): mean (SD) 62.8 (10.0) Total abdominal hysterectomy (TAH): Mean (SD) 62.7 (9.7)	361	332	FACT-G; EnWB (FACT subscale Endometrial) (FACT-G+ EnWB= FACT- Endometrial) Body image scale; EQ-5D (EuroQoL-VAS).	Patient Reported Outcomes (PRO) (including QOL or symptoms relief). QoL at 6 months.	Total laparoscopic hysterectomy (TLH). Total abdominal hysterectomy (TAH).	Operating time was significantly longer in the TLH group (138 min [SD 43]) than in the TAH group (109 min [SD 34]; p=0.001). Postoperatively, twice as many patients in the TAH group experienced adverse events of grade 3 or higher (33 of 142 [23.2%] vs 22 of 190 [11.6%] in the TLH group; p=0.004). Postoperative serious adverse events occurred more in the TAH group (27 of 142 [19.0%]) than in the TLH group (16 of 190 [7.9%]; p=0.002).	Patients who had TLH reported significantly greater improvement in QoL from baseline compared wit those that had TAH, in all subscales apart from emotional and social well-being. Improvements in QoL up to 6 months after surgery continued to favor TLH, except in the emotional and social well-being measures of the FACT and the visual analogue scaled of the EuroQol-VAS. The greatest differences were noted in FWB (13% greater improvement for patients with TLH), PWB (11%), EnWB (6%), and the overallFACT-G summary score (7%; p=0.001 for all comparisons). Patients in the TLH group also reported a 5% (p=0.001) greater improvement in body image and 7.5% (p=0.001) greater improvement in overall QoL (EuroQoL- VAS) than patients in the TAH group. During the late post-op	Endometrial

									recovery phase (3–6 mths after surg),TLH patients recovered significantly more in their physical, (p=0.008), functional (p=0.009), endometrial cancer-specific (p=0.003), and overall wellbeing (FACT- G; p=0.03), and also had better QoL recovery with regard to body image (p=0.001)	
Mourits MJ et al. Lancet Oncol 2010; 11(8):763-71; Bijen CB et al. Gynecol Oncol 2011; 121(1):76-82.	No	Total abdominal hysterectomy (TLH): n=185 median: 62 range 40-89; Total abdominal hysterectomy (TAH): n=94 median 63 range 39-86	283	0	SF-36, SAQ, BIS, VAS for general health perception. EQ-5D.	Major complication rate.	Total abdominal hysterectomy (TAH) and bilateral salpingo- oophorectomy vs Total laparoscopic hysterectomy (TLH) and bilateral salpingo- oophorectomy.	The proportion of major complications was 14.6% (27 of 185) in the TLH group versus 14.9% (14 of 94) in the TAH group, with a diff erence of -0.3% (95% CI -9.1 to 8.5; p=0.95).TLH was associated with signifi cantly less blood loss (p<0.0001), less use of pain medication (p<0.0001), a shorter hospital stay (p<0.0001), and a faster recovery (p=0.002), but the procedure took longer than TAH (p<0.0001).	A higher percentage of patients in TLH group (76.3%) resumed daily activities after 6 weeks than in TAH group (62.2%). Patients who had TLH scored significantly higher on the physical functioning subscale of the SF-36 at 6 weeks, and on the role-physical subscale at 3 months after the procedure. Patients who had TAH scored signific cantly higher on the vitality subscale of the mental dimension 3 months after surgery.	Endometrial
	<u> </u>	1	1	Mixed diseas	e stage (loco-regiona	l disease and n	netastatic disease)		Surgery.	
Walker JL et al. J Clin Oncol 2009; 27(32):5331-6; Kornblith AB et al. J Clin Oncol 2009; 27(32):5337- 42; Walker JL et al. J Clin Oncol 2012; 30(7):695-700.	Yes	Median (Range) Laparoscopy 62.8 (55.4-71.6) Laparotomy 62.7 (54.9-70.6)	2616	727	FACT-G; AP MOS-SF36; PF BPI; BI.	Recurrence free servival.	Patients with clinical stage I to IIA uterine cancer were randomly assigned to laparoscopy (n 1,696) or open laparotomy (n 920), including hysterectomy, salpingo- oophorectomy, pelvic cytology, and pelvic and para-aortic lymphadenectomy	Laparoscopy had fewer moderate to severe postoperative adverse events than laparotomy (14% v 21%, respectively; P < 0.0001); significantly longer operative time (median, 204 v 130 minutes, respectively; P < 0.001). Hospitalization of more than 2 days was significantly lower in laparoscopy versus laparotomy patients (52% v 94%, respectively; P < 0.0001). Pelvic and para-aortic nodes were not removed in 8% of laparoscopy patients and 4%	In an intent-to-treat analysis, laparoscopy patients reported significantly higher Functional Assessment of Cancer therapy–General (FACT-G) scores (P = 0.001), better physical functioning (P = 0.006), better body image (BI; P < 0.001), less pain (P < 0.001), less pain (P < 0.001), and its interference with QoL (P <0.001), and an earlier resumption of normal activities (P = 0.003) and return to work (P = 0.04) over the 6-week postsurgery period, as compared with laparotomy	Endometrial

Greimel ER et al. J Clin Oncol 2006; 24(4):579-86; du Bois AJ et	Yes	mean 56.7, Standard deviation (SD) 10.93; range 20.8- 77.4 and 57.7	798	TC: 397 eligible, 366 forms returned PT : 386 eligible, 357	EORTC QLQ- C30	progression free- survival.	Paclitaxel (185 mg/m2) + carboplatin (AUC=6) (TC arm) vs. paclitaxel (185 mg/m2) +	of laparotomy patients (P <0.0001). The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5%	patients. By 6 months, the only difference between arms was the better BI in laparoscopy. Patients in the TC arm showed better means scores after treatment on overall QoL overall QoL (P=0.012), physical functioning (P= 0.012),	Ovarian
al. J Natl Cancer Inst. 2003;95(17):13 20-9. Hilpert F et al. Ann Oncol 2007; 18(2):282-7.		SD 10.11; range 25.4- 83.6 in the paclitaxel plus carboplatin (TC) and paclitaxel plus cisplatin (PT)		forms returned			cisplatin 75 mg/m2 (PT arm) - all six courses per 3 weeks	for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = $-\infty$ to 8.2%). Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different; the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	role functioning (P = 0.005), and cognitive functioning (P = 0.024), compared with the PT arm. Concerning symptom experience, patients undergoing TC showed less nausea and vomiting (P < 0.001), less appetite loss (P< 0.001), and less fatigue (P= 0.033) after completion of treatment compared with patients undergoing PT.	
Carey MS et al. Gynecol Oncol 2008; 108(1):100-5; Butler L et al. J Clin Oncol 2004; 22(12):2461-8; Piccart MJ J Natl Cancer Inst 2000; 92(9):699-708; Bezjak A et al. J Clin Oncol 2004;22(22):45 95-603.	Yes	Median (Range) Cyclophospha mide (CP): 58 (22-85) paclitaxel (TP): 58 (23-79)	680	152	EORTC QLQ- C30	progression free- survival.	TP arm= paclitaxel at a dose of 175 mg/m2 as a 3- hour infusion followed by cisplatin at a dose of 75 mg/m2 CP arm= cyclophosphamide at 750 mg/m2 followed by cisplatin at 75 mg/m2. Duration every 3 weeks between 3 and 9 cycles.	At a median follow-up of 38.5 months and despite a high rate of crossover (48%) from the cyclophosphamide arm to the paclitaxel arm at first detection of progression of disease, a longer progression-free survival (log-rank P = 0.0005 ; median of 15.5 months versus 11.5 months) and a longer overall survival (log-rank P = 0.0016 ; median of 35.6 months versus 25.8 months) were seen in the paclitaxel regimen compared with the cyclophosphamide regimen.	Clinically meaningful improvements compared with baseline (change scores > 10) were found in both arms during the treatment period in a number of domains and items, including global QOL, emotional function, social function, fatigue, pain, sleep, constipation, appetite, abdominal swelling, and abdominal cramps. Improvements in global QOL persisted for the duration of follow-up. More neurosensory effects and myalgia were found in the paclitaxel arm.	Ovarian
Wenzel L et al. J Clin Oncol 2005; 23(24):5605-	No	Median (range) Secondary	550	376	FACT-G; FACT-O; GOG (supplemental	overall survival.	Name drugs: paclitaxel + cisplatin	No statistically significant differences.	For all patients, QOL decreased approximately 1 unit from the first to second assessment.	Ovarian.

1 1/1.	,						D <i>C</i>		a: :a :	1
12;		surgery plus			questions)		Doses: Chemo		Significant improvement	
		chemotherapy					only: paclitaxel		observed at 6 months (P $<$	
Rose PG et al.		group: 58.1					135 mg/m2 over		0.001) was sustained at 12	
N Engl J Med		(25.4-81.6)					24 hours followed		months, with no	
2004;351(24):2		(20.1.01.0)					by immediately by		appreciable between-group	
		Channe the server								
489-97.		Chemotherap					cisplating Cis 75		difference (P=0.048). The	
		y-alone					mg/m2;		baseline FACT-O score	
		group:							was associated with overall	
		57.0 (27.0-					Duration:		survival (P =0.048) but not	
		81.6)					maximum of 6		progression-free survival.	
		01.0)					cycles of 3 weeks		Less neurotoxicity was	
							Cycles of 5 weeks			
									reported among patients	
									who did (38.4%) versus	
							Surgery + chemo:		did not (54.0%) undergo	
							paclitaxel 135		interval secondary	
							mg/m2 over 24		cytoreduction at the third	
							hours followed by		assessment ($P=0.005$), and	
							immediately by		older patients experienced	
							cisplating Cis 75		more long-term effects.	
							mg/m2 every 3			
							weeks for max 6			
							cycles. Secondary			
							cytoreduction			
							performed as soon			
							as possible after			
							hematologic			
							recovery of the			
							3rd cycle, but			
							within six weeks			
							after the			
							completion of the			
							third cycle.			
							2			
Nout RA et al.	No									
Lancet 2010;		pelvic	427	0	EORTC OLO-	vaginal	vaginal	No significant differences	Patients in the VBT group	Endometrial
Lancet 2010,	110	pelvic external beam	427	0	EORTC QLQ-	vaginal	vaginal brachytherapy	No significant differences	Patients in the VBT group	Endometrial
	110	external beam	427	0	C30	vaginal recurrence.	brachytherapy	between arms regarding	reported better social	Endometrial
375(9717):816-	1.0	external beam radiotherapy	427	0	C30 version 3.0;	-	brachytherapy (VBT) =		reported better social functioning (P<0.002) and	Endometrial
	1.0	external beam radiotherapy (EBRT)=	427	0	C30 version 3.0; subscales for	-	brachytherapy (VBT) = 1. High–dose-	between arms regarding vaginal recurrence.	reported better social functioning (P<0.002) and lower symptom scores for	Endometrial
375(9717):816-		external beam radiotherapy	427	0	C30 version 3.0;	-	brachytherapy (VBT) =	between arms regarding	reported better social functioning (P<0.002) and	Endometrial
375(9717):816- 23;		external beam radiotherapy (EBRT)= Median 69	427	0	C30 version 3.0; subscales for bowel and bladder	-	brachytherapy (VBT) = 1. High–dose- rate (HDR).	between arms regarding vaginal recurrence. Rates of acute grade 1–2	reported better social functioning (P<0.002) and lower symptom scores for diarrhea, fecal leakage, the	Endometrial
375(9717):816- 23; Nout RA et al.		external beam radiotherapy (EBRT)=	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were	reported better social functioning (P<0.002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer		external beam radiotherapy (EBRT)= Median 69 (SD:7);	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the	reported better social functioning (P<0.002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT	reported better social functioning (P<0.002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic	reported better social functioning (P<0.002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)=	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy	reported better social functioning (P <0.002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P <0.001). At baseline,	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy,	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic	reported better social functioning (P<0.002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16 38-48; Nout RA et al.		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)= Median:70	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for sexual functioning	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy, 1 week apart for	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy EBRT group at completion of	reported better social functioning (P<0.002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P<0.001). At baseline, 15% of patients were	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16 38-48; Nout RA et al. J Clin Oncol		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)=	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for sexual functioning and symptoms	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy, 1 week apart for the high-dose rate;	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy EBRT group at completion of radiotherapy (12.6% [27/215]	reported better social functioning (P<0.002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P<0.001). At baseline, 15% of patients were sexually active; this	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16 38-48; Nout RA et al. J Clin Oncol 2009;		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)= Median:70	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for sexual functioning and symptoms from Ovarian	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy, 1 week apart for the high-dose rate; 2. Low-dose rate	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy EBRT group at completion of	reported better social functioning (P<0.002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P<0.001). At baseline, 15% of patients were sexually active; this increased significantly to	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16 38-48; Nout RA et al. J Clin Oncol 2009; 27(21):3547-		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)= Median:70	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for sexual functioning and symptoms from Ovarian Cancer Module	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy, 1 week apart for the high–dose rate; 2. Low-dose rate (LDR) schedules:	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy EBRT group at completion of radiotherapy (12.6% [27/215]	reported better social functioning (P<0.002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P<0.001). At baseline, 15% of patients were sexually active; this increased significantly to 39% during the first year	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16 38-48; Nout RA et al. J Clin Oncol 2009;		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)= Median:70	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for sexual functioning and symptoms from Ovarian	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy, 1 week apart for the high-dose rate; 2. Low-dose rate (LDR) schedules: 30 Gy at 50–70	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy EBRT group at completion of radiotherapy (12.6% [27/215]	reported better social functioning ($P<0.002$) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms ($P<0.001$). At baseline, 15% of patients were sexually active; this increased significantly to 39% during the first year ($P<0.001$). Sexual	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16 38-48; Nout RA et al. J Clin Oncol 2009; 27(21):3547-		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)= Median:70	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for sexual functioning and symptoms from Ovarian Cancer Module	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy, 1 week apart for the high-dose rate; 2. Low-dose rate (LDR) schedules: 30 Gy at 50–70	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy EBRT group at completion of radiotherapy (12.6% [27/215]	reported better social functioning (P<0.002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P<0.001). At baseline, 15% of patients were sexually active; this increased significantly to 39% during the first year (P<0.001). Sexual functioning and symptoms	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16 38-48; Nout RA et al. J Clin Oncol 2009; 27(21):3547-		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)= Median:70	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for sexual functioning and symptoms from Ovarian Cancer Module	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy, 1 week apart for the high-dose rate; 2. Low-dose rate (LDR) schedules: 30 Gy at 50–70 cGy/h	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy EBRT group at completion of radiotherapy (12.6% [27/215]	reported better social functioning (P<0.002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P<0.001). At baseline, 15% of patients were sexually active; this increased significantly to 39% during the first year (P<0.001). Sexual functioning and symptoms	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16 38-48; Nout RA et al. J Clin Oncol 2009; 27(21):3547-		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)= Median:70	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for sexual functioning and symptoms from Ovarian Cancer Module	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy, 1 week apart for the high-dose rate; 2. Low-dose rate (LDR) schedules: 30 Gy at 50–70 cGy/h 3. Medium-dose-	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy EBRT group at completion of radiotherapy (12.6% [27/215]	reported better social functioning ($P<0.002$) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms ($P<0.001$). At baseline, 15% of patients were sexually active; this increased significantly to 39% during the first year ($P<0.001$). Sexual functioning and symptoms did not differ between the	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16 38-48; Nout RA et al. J Clin Oncol 2009; 27(21):3547-		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)= Median:70	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for sexual functioning and symptoms from Ovarian Cancer Module	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy, 1 week apart for the high-dose rate; 2. Low-dose rate (LDR) schedules: 30 Gy at 50–70 cGy/h 3. Medium-dose- rate. (MDR)	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy EBRT group at completion of radiotherapy (12.6% [27/215]	reported better social functioning (P<0.002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P<0.001). At baseline, 15% of patients were sexually active; this increased significantly to 39% during the first year (P<0.001). Sexual functioning and symptoms	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16 38-48; Nout RA et al. J Clin Oncol 2009; 27(21):3547-		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)= Median:70	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for sexual functioning and symptoms from Ovarian Cancer Module	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy, 1 week apart for the high-dose rate; 2. Low-dose rate (LDR) schedules: 30 Gy at 50–70 cGy/h 3. Medium-dose- rate. (MDR) schedules: 28 Gy	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy EBRT group at completion of radiotherapy (12.6% [27/215]	reported better social functioning ($P<0.002$) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms ($P<0.001$). At baseline, 15% of patients were sexually active; this increased significantly to 39% during the first year ($P<0.001$). Sexual functioning and symptoms did not differ between the	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16 38-48; Nout RA et al. J Clin Oncol 2009; 27(21):3547-		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)= Median:70	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for sexual functioning and symptoms from Ovarian Cancer Module	-	brachytherapy (VBT) = 1. High-dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy, 1 week apart for the high-dose rate; 2. Low-dose rate (LDR) schedules: 30 Gy at 50–70 cGy/h 3. Medium-dose- rate. (MDR) schedules: 28 Gy at 100 cGy/h in	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy EBRT group at completion of radiotherapy (12.6% [27/215]	reported better social functioning ($P<0.002$) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms ($P<0.001$). At baseline, 15% of patients were sexually active; this increased significantly to 39% during the first year ($P<0.001$). Sexual functioning and symptoms did not differ between the	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16 38-48; Nout RA et al. J Clin Oncol 2009; 27(21):3547-		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)= Median:70	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for sexual functioning and symptoms from Ovarian Cancer Module	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy, 1 week apart for the high-dose rate; 2. Low-dose rate (LDR) schedules: 30 Gy at 50–70 cGy/h 3. Medium-dose- rate. (MDR) schedules: 28 Gy	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy EBRT group at completion of radiotherapy (12.6% [27/215]	reported better social functioning ($P<0.002$) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms ($P<0.001$). At baseline, 15% of patients were sexually active; this increased significantly to 39% during the first year ($P<0.001$). Sexual functioning and symptoms did not differ between the	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16 38-48; Nout RA et al. J Clin Oncol 2009; 27(21):3547-		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)= Median:70	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for sexual functioning and symptoms from Ovarian Cancer Module	-	brachytherapy (VBT) = 1. High–dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy, 1 week apart for the high-dose rate; 2. Low-dose rate (LDR) schedules: 30 Gy at 50–70 cGy/h 3. Medium-dose- rate. (MDR) schedules: 28 Gy at 100 cGy/h in one session.	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy EBRT group at completion of radiotherapy (12.6% [27/215]	reported better social functioning ($P<0.002$) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms ($P<0.001$). At baseline, 15% of patients were sexually active; this increased significantly to 39% during the first year ($P<0.001$). Sexual functioning and symptoms did not differ between the	Endometrial
375(9717):816- 23; Nout RA et al. Eur J Cancer 2012;48(11):16 38-48; Nout RA et al. J Clin Oncol 2009; 27(21):3547-		external beam radiotherapy (EBRT)= Median 69 (SD:7); vaginal brachytherapy (VBT)= Median:70	427	0	C30 version 3.0; subscales for bowel and bladder symptoms from from the prostate cancer module (PR25) and subscale for sexual functioning and symptoms from Ovarian Cancer Module	-	brachytherapy (VBT) = 1. High-dose- rate (HDR). schedules aimed at 45-50 Gy by schedules of 21 Gy in three fractions of 7 Gy, 1 week apart for the high-dose rate; 2. Low-dose rate (LDR) schedules: 30 Gy at 50–70 cGy/h 3. Medium-dose- rate. (MDR) schedules: 28 Gy at 100 cGy/h in	between arms regarding vaginal recurrence. Rates of acute grade 1–2 gastrointestinal toxicity were signifi cantly lower in the vaginal brachytherapy VBT group than in the pelvic external beam radiotherapy EBRT group at completion of radiotherapy (12.6% [27/215]	reported better social functioning ($P<0.002$) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms ($P<0.001$). At baseline, 15% of patients were sexually active; this increased significantly to 39% during the first year ($P<0.001$). Sexual functioning and symptoms did not differ between the	Endometrial

							(EBRT) = A dose of 46 Gy 2 Gy fractions, five times per week, duration unclear.			
Randall ME et al. J Clin Oncol 2006; 24(1):36- 44; Bruner DW et al. Qual Life Res 2007;16(1):89- 100.	No	Median =63	422	317	FS; APN; FACE; FACT-G.	progression free- survival.	Whole-abdominal irradiation (WAI): irradiation (WAI): irradiation dose was 30Gyin 20 daily fractions. After WAI, patients received a boost to the true pelvis or to an extended field encompassing pelvic lymph nodes (PLNs) and positive para-aortic lymph nodes (PALNs). The boost dose was 15 Gy in 8 fractions. All fields were treated once daily, 5 days per week. AP: chemotherapy; doxorubicin 60 mg/m2 plus cisplatin 50 mg/m2 every 3 weeks for seven cycles, followed by 1 cycle of cisplatin.	hazard ratio was 0.68 (95% CI, 0.52 to 0.89; P =0.01) favoring AP. At 60 months and adjusting for stage, 55% of AP patients were predicted to be alive compared with 42% of WAI patients (HR: 0.68; 95% CI: 0.52–0.89, p<0.01).	WAI patients reported worse FS (p<0.001) and FACE (p<0.001) scores at end of treatment and poorer FACE scores 3 months post-treatment (p = 0.004) compared to AP patients. APN scores were significantly worse among AP patients at end of treatment, and 3 and 6 months post-treatment (p<0.001 for all). FACT-G scores did not differ between the two arms at any assessment point.	Endometrial
Wilkinson PM et al. Br J Cancer 2006; 94(7):947-54.	Yes	mean: Epoetin alfa =59.1 (+- 10.6) (range 35-87) Best standard treatment = 60.3 (+-11.2) (range (30-79)	182	102	FACT-G, FACT- An, CLAS; LASA	Changes in haemoglobi n (Hb) level from baseline to study end.	Epoetin alfa 10 000–20 000 IU three times weekly plus best standard treatment (BST= transfusion of red blood cells, as needed) / BST only. The planned duration of study treatment was a maximum of 28 weeks, which included 18–24 weeks of chemotherapy (maximum, six cycles) plus up to 4 weeks after the last chemotherapy dose.	For the epoetin alfa group, mean Hb increased by 1.8 g dl(raise to the -1power) by weeks 4–6 and was significantly increased from baseline through study end (P<0.001). The mean change in Hb from baseline was significantly (P<0.001) greater for epoetin alfa than BST patients at all postbaseline evaluations. Significantly fewer epoetin alfa than BST patients required transfusion(s) after the first 4 weeks of treatment (7.9 vs 30.5%; P<0.001).	Significant differences from baseline favouring epoetin alfa over BST for all three CLAS change scores (Energy Level, Ability to Do Daily Activities, Overall QOL) and the average median CLAS change score during chemotherapy.	Ovarian

1 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	ease stage
Alvarez Secord Act al. Cancer 2012;118(13):3 283-93; Pokrzywinski R t al. Gynecol Dncol 2011;123(3):50 5-10; Havrilesky LJ et al. Cancer 2012; 118(2):386-91. No Portage And Carboplatin (cDC): 53.8 / 64 (10.2) Sequential Docetaxel and Carboplatin (sDC): 53.0 / 64.5 (10.0) (39-82) No Progre free- surviva Progre free- Progre free- surviva Progre free- surviva Progre free- surviva Progre free- surviva Progre free- surviva Progre free- f	sion Name drugs: The median progression-free Sequential docetaxel Multiple disease docetaxel & survival (PFS) was 13.7 followed by carboplatin sites

Legend:

* No ranking was made based on level or reporting in this table. Studies are ordered by overall number of patients recruited in the study. † Data are reported so as available in the paper.

Abbreviations:

EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30; EORTC QLQ-OV28: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Ovarian Module-28; AUC: area under the curve; FACT-G: Functional Assessment of Cancer Therapy - General; FACT-Cx: Functional Assessment of Cancer Therapy-Cervix; TOI: Trial Outcome Index; FACT/GOG-NTX: Functional Assessment of Cancer Therapy/Gynecologic Oncology Group -Neurotoxicity four-item scale; UNI=UNISCALE ; BPI-SF: Brief Pain Inventory- short form; FACT-O: Functional Assessment of Cancer Therapy – Ovarian ; EQ-5D: European Quality of Life-5 Dimensions; VAS: visual analogue scale; SF-36: The Medical Outcomes Study Short Form 36-Item Health Survey; SAQ: the Sexual Activity Questionnaire; BIS: Body Image Scale; MOS-SF36 PF: The Physical Functioning Subscale of the Medical Outcome Study–Short Form; AP: Additional Treatment Related Symptoms; BI: Body Image; APN: Assessment for Peripheral Neuropathy Scale; FS: Fatigue Scale; FACE: Functional Alterations due to Changes in Elimination; FACT-An: the Fact-Anaemia; CLAS: Cancer Linear Analog Scale; LASA: Linear Analog Scale Assessment.

Figure 2.

Risk bar chart showing risk of bias across RCTs by quality of PRO studies.

